Abstract-We examined the effects of the vasodilator peptide adrenomedullin (AM) infused intravenously into subjects with essential hypertension. Eight men 39 to 58 years old with uncomplicated hypertension (147/96Ϯ5/3 mm Hg at baseline) were studied in a placebo-controlled, crossover design. Each subject received intravenous AM in a low and a high dose (2.9 and 5.8 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 for 2 hours each) or vehicle-control (Hemaccel) infusion in a random order on day 4 of a controlled metabolic diet (80 mmol/d Na ϩ , 100 mmol/d K ϩ ). Plasma AM reached pathophysiological levels during infusion (18Ϯ4 pmol/L in low dose, 34Ϯ9 pmol/L in high dose) with a concurrent rise in plasma cAMP (ϩ8.4Ϯ1.2 pmol/L, PϽ0.05 compared with control). Compared with control, high-dose AM increased peak heart rate (ϩ17.8Ϯ2.3 bpm, PϽ0.01), lowered systolic (Ϫ24.6Ϯ0.9 mm Hg; PϽ0.01) and diastolic (Ϫ21.9Ϯ1.4 mm Hg; PϽ0.01) blood pressure, and increased cardiac output (ϩ1.0Ϯ0.1 L/min in low dose, ϩ2.9Ϯ0.2 L/min in high dose; PϽ0.01 for both). Despite a rise in plasma renin activity during high dose (PϽ0.05), aldosterone levels did not alter. Plasma norepinephrine levels increased 1295Ϯ222 pmol/L (PϽ0.001) and epinephrine increased 74Ϯ15 pmol/L (PϽ0.05) with high-dose AM compared with control. AM had no significant effect on urine volume and sodium excretion. In subjects with essential hypertension, the intravenous infusion of AM to achieve pathophysiological levels produced significant falls in arterial pressure, increased heart rate and cardiac output, and stimulated the sympathetic system and renin release without concurrent increase in aldosterone. Urinary parameters were unaltered. Although AM has potent hemodynamic and neurohumoral effects in subjects with essential hypertension, the threshold for urinary actions is set higher. (Hypertension. 2000;36:588-593.) Key Words: hypertension, essential Ⅲ adrenomedullin Ⅲ renin Ⅲ nervous system, sympathetic Ⅲ blood pressure Ⅲ cardiac output A drenomedullin (AM) is a 52-amino-acid vasodilator peptide isolated in 1993 from human pheochromocytoma. 1 The AM gene, located on chromosome 11 in humans, 2 is expressed in numerous tissues, 3,4 and the peptide itself appears ubiquitous presumably because high rates of gene transcription and synthesis occur in vascular smooth muscle cells (VSMCs) and endothelial cells. [5][6][7][8] Available studies, although far from being definitive, suggest that AM may contribute to homeostatic responses, at least in sepsis 9 and some cardiovascular disorders. 10 -12 Its potent vasodilator action is well documented 1,13-15 and is likely mediated through NO-and cAMP-dependent mechanisms. 16 AM is present in the central nervous system and may have a role in the modulation of salt appetite, thirst, and sympathetic activity. 16 -18 In some models, AM increases glomerular filtration rate and has a natriuretic action. 16 AM also interacts with other hormones; for example, inhibiting the secretion of aldosterone in the adrenal zona glomerulosa 19 and endothelin-1 in VSMCs. ...